491 related articles for article (PubMed ID: 24408866)
1. Potential targeted therapy for liver fluke associated cholangiocarcinoma.
Vaeteewoottacharn K; Seubwai W; Bhudhisawasdi V; Okada S; Wongkham S
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):362-70. PubMed ID: 24408866
[TBL] [Abstract][Full Text] [Related]
2. MET‑RON dual inhibitor, BMS‑777607, suppresses cholangiocarcinoma cell growth, and MET‑RON upregulation indicates worse prognosis for intra‑hepatic cholangiocarcinoma patients.
Cheng CT; Chen YY; Wu RC; Tsai CY; Chiang KC; Yeh TS; Chen MH; Yeh CN
Oncol Rep; 2018 Sep; 40(3):1411-1421. PubMed ID: 30015968
[TBL] [Abstract][Full Text] [Related]
3. PRKAR1A overexpression is associated with increased ECPKA autoantibody in liver fluke-associated cholangiocarcinoma: application for assessment of the risk group.
Loilome W; Yooyuen S; Namwat N; Sithithaworn P; Puapairoj A; Kano J; Noguchi M; Miwa M; Yongvanit P
Tumour Biol; 2012 Dec; 33(6):2289-98. PubMed ID: 22922884
[TBL] [Abstract][Full Text] [Related]
4. Molecular aspects of cholangiocarcinoma.
Kiguchi K
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):371-9. PubMed ID: 24420749
[TBL] [Abstract][Full Text] [Related]
5. Overexpression of microRNA-21 regulating PDCD4 during tumorigenesis of liver fluke-associated cholangiocarcinoma contributes to tumor growth and metastasis.
Chusorn P; Namwat N; Loilome W; Techasen A; Pairojkul C; Khuntikeo N; Dechakhamphu A; Talabnin C; Chan-On W; Ong CK; Teh BT; Yongvanit P
Tumour Biol; 2013 Jun; 34(3):1579-88. PubMed ID: 23417858
[TBL] [Abstract][Full Text] [Related]
6. Discovering proteins for chemoprevention and chemotherapy by curcumin in liver fluke infection-induced bile duct cancer.
Khoontawad J; Intuyod K; Rucksaken R; Hongsrichan N; Pairojkul C; Pinlaor P; Boonmars T; Wongkham C; Jones A; Plieskatt J; Potriquet J; Bethony JM; Mulvenna J; Pinlaor S
PLoS One; 2018; 13(11):e0207405. PubMed ID: 30440021
[TBL] [Abstract][Full Text] [Related]
7. Ultrasonography as a tool for monitoring the development and progression of cholangiocarcinoma in Opisthorchis viverrini/ dimethylnitrosamine-induced hamsters.
Plengsuriyakarn T; Eursitthichai V; Labbunruang N; Na-Bangchang K; Tesana S; Aumarm W; Pongpradit A; Viyanant V
Asian Pac J Cancer Prev; 2012; 13(1):87-90. PubMed ID: 22502719
[TBL] [Abstract][Full Text] [Related]
8. Fibroblast growth factor receptor 2 fusions as a target for treating cholangiocarcinoma.
Borad MJ; Gores GJ; Roberts LR
Curr Opin Gastroenterol; 2015 May; 31(3):264-8. PubMed ID: 25763789
[TBL] [Abstract][Full Text] [Related]
9. Cholangiocarcinoma: molecular pathways and therapeutic opportunities.
I Ilyas S; Borad MJ; Patel T; Gores GJ
Semin Liver Dis; 2014 Nov; 34(4):456-64. PubMed ID: 25369307
[TBL] [Abstract][Full Text] [Related]
10. A novel carbohydrate antigen expression during development of Opisthorchis viverrini- associated cholangiocarcinoma in golden hamster: a potential marker for early diagnosis.
Sawanyawisuth K; Silsirivanit A; Kunlabut K; Tantapotinan N; Vaeteewoottacharn K; Wongkham S
Parasitol Int; 2012 Mar; 61(1):151-4. PubMed ID: 21784171
[TBL] [Abstract][Full Text] [Related]
11. Methionine aminopeptidase 2 over-expressed in cholangiocarcinoma: potential for drug target.
Sawanyawisuth K; Wongkham C; Pairojkul C; Saeseow OT; Riggins GJ; Araki N; Wongkham S
Acta Oncol; 2007; 46(3):378-85. PubMed ID: 17450475
[TBL] [Abstract][Full Text] [Related]
12. STATs profiling reveals predominantly-activated STAT3 in cholangiocarcinoma genesis and progression.
Dokduang H; Techasen A; Namwat N; Khuntikeo N; Pairojkul C; Murakami Y; Loilome W; Yongvanit P
J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):767-76. PubMed ID: 25044480
[TBL] [Abstract][Full Text] [Related]
13. Perturbation of proteasome function by bortezomib leading to ER stress-induced apoptotic cell death in cholangiocarcinoma.
Vaeteewoottacharn K; Kariya R; Matsuda K; Taura M; Wongkham C; Wongkham S; Okada S
J Cancer Res Clin Oncol; 2013 Sep; 139(9):1551-62. PubMed ID: 23877657
[TBL] [Abstract][Full Text] [Related]
14. Combining biological agents and chemotherapy in the treatment of cholangiocarcinoma.
Jensen LH; Jakobsen A
Expert Rev Anticancer Ther; 2011 Apr; 11(4):589-600. PubMed ID: 21504326
[TBL] [Abstract][Full Text] [Related]
15. Cyclophilin A enhances cell proliferation and tumor growth of liver fluke-associated cholangiocarcinoma.
Obchoei S; Weakley SM; Wongkham S; Wongkham C; Sawanyawisuth K; Yao Q; Chen C
Mol Cancer; 2011 Aug; 10():102. PubMed ID: 21871105
[TBL] [Abstract][Full Text] [Related]
16. Expression of oxysterol binding protein isoforms in opisthorchiasis-associated cholangiocarcinoma: a potential molecular marker for tumor metastasis.
Loilome W; Wechagama P; Namwat N; Jusakul A; Sripa B; Miwa M; Kuver R; Yongvanit P
Parasitol Int; 2012 Mar; 61(1):136-9. PubMed ID: 21763455
[TBL] [Abstract][Full Text] [Related]
17. Systemic therapy of cholangiocarcinoma: From chemotherapy to targeted therapies.
Schweitzer N; Vogel A
Best Pract Res Clin Gastroenterol; 2015 Apr; 29(2):345-53. PubMed ID: 25966433
[TBL] [Abstract][Full Text] [Related]
18. Combined targeting of AKT and mTOR using MK-2206 and RAD001 is synergistic in the treatment of cholangiocarcinoma.
Ewald F; Grabinski N; Grottke A; Windhorst S; Nörz D; Carstensen L; Staufer K; Hofmann BT; Diehl F; David K; Schumacher U; Nashan B; Jücker M
Int J Cancer; 2013 Nov; 133(9):2065-76. PubMed ID: 23588885
[TBL] [Abstract][Full Text] [Related]
19. The Hallmarks of Liver Fluke Related Cholangiocarcinoma: Insight into Drug Target Possibility.
Loilome W; Namwat N; Jusakul A; Techasen A; Klanrit P; Phetcharaburanin J; Wangwiwatsin A
Recent Results Cancer Res; 2023; 219():53-90. PubMed ID: 37660331
[TBL] [Abstract][Full Text] [Related]
20. Protein Kinases as Targets for Opisthorchis viverrini- Associated Cholangiocarcinoma Therapy.
Loilome W; Dokduang H
Curr Pharm Des; 2017 Nov; 23(29):4281-4289. PubMed ID: 28699535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
